Skip to main content

News

Latest News

April 1, 2021

Washington D.C. – Today, Reps. Adam Schiff (D-CA) and Carolyn B. Maloney (D-NY), along with Reps. Barbara Lee (D-CA), Mike Quigley (D-IL), Katherine Clark (D-MA), Jamie Raskin (D-MD), Alexandria Ocasio-Cortez (D-NY), Chris Pappas (D-NH), and Ritchie Torres (D-NY) introduced a resolution highlighting the urgent need for nondiscriminatory and equitable blood and blood product donation policies in the United States.


April 1, 2021

Washington, D.C. (Apr. 1, 2021)—Today, Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, issued this statement following release of the Office of National Drug Control Policy's (ONDCP) Drug Control Policy Statement:

"I am pleased to see the Biden-Harris Administration's ONDCP meet its first benchmark in the timely release of the required Drug Control Policy Statement, especially after the failures of the last administration.

Issues: Administration

April 1, 2021

WASHINGTON, D.C. The U.S. Government Accountability Office (GAO) released a new report reviewing the government funding that led to the development of the drug Remdesivir, which costs $3,120 for a five day course of treatment.


March 31, 2021

Washington, D.C. (Mar. 31, 2021)—On Wednesday, April 14, 2021, at 10:00 a.m., Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, along with Committee Member Congresswoman Eleanor Holmes Norton, will hold a business meeting on H.R. 51, the Washington, D.C. Admission Act, introduced by Congresswoman Norton on January 4, 2021.

Issues: DC

March 31, 2021
Washington, D.C. (Mar. 31, 2021)—Today, Oversight and Reform Committee Chairwoman Carolyn B. Maloney, Ranking Member James Comer, Government Operations Subcommittee Chairman Gerald E. Connolly, and Ranking Member Jody B. Hice sent letters to 23 agencies requesting their current policies for interacting with Inspectors General and cooperating with Inspector General investigations.

March 31, 2021

Washington D.C. (March 31, 2021)—Chairman James E. Clyburn and all Democratic Members of the Select Subcommittee on the Coronavirus Crisis sent letters to the Department of Health and Human Services, the Department of Homeland Security, the Federal Emergency Management Agency, and the National Archives as part of an ongoing investigation into the Trump Administration's efforts to procure and distribute personal protective equipment (PPE) and other critical supplies during the pandemic. The Select Subcommittee also released new documents obtained in this investigation.


March 25, 2021

Washington, D.C. (March 25, 2021)—Today, Committee and Subcommittee Chairs across the House of Representatives sent letters to the White House, federal agencies, law enforcement, and Legislative Branch entities, including the House and Senate Sergeant at Arms, seeking documents and communications relating to the January 6, 2021, domestic terrorist assault on the Capitol.

Issues: DC

March 25, 2021

Washington, D.C. (March 25, 2021) — Today, the Select Subcommittee on the Coronavirus Crisis, chaired by Rep. James E. Clyburn, held a hearing to examine the fraud risks in small business pandemic relief programs, including nearly $84 billion in potential fraud in the Small Business Administration's (SBA) Economic Injury Disaster Loan (EIDL) program and the Paycheck Protection Program (PPP).


March 25, 2021

Washington, D.C. (March 25, 2021) — Today, Rep. James E. Clyburn, Chairman of the Select Subcommittee on the Coronavirus Crisis, delivered the following remarks at the Pandemic Response Accountability Committee (PRAC) and the Partnership for Public Service's virtual forum reflecting on one year since the passage of the CARES Act and oversight of America's pandemic response:


March 25, 2021

Washington, D.C. (March 25, 2021) —Today, Rep. James E. Clyburn, Chairman of the Select Subcommittee on the Coronavirus Crisis, issued the following statement in response to the Biden-Harris Administration's announcement that it is investing $10 billion in initiatives that will expand access to coronavirus vaccines and build vaccine confidence in communities that have been hardest hit by and are at highest risk from the coronavirus: